Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Invasive Bladder Cancer × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 27 Lung Neoplasms 12 Colorectal Neoplasms 11 Ovarian Neoplasms 10 Breast Neoplasms 10 Small Cell Lung Carcinoma 8 Urinary Bladder Neoplasms 7 Recurrence 6 Prostatic Neoplasms 6 Neoplasms 6 Head and Neck Neoplasms 6 Triple Negative Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Pancreatic Neoplasms 5 Diabetes Mellitus, Insulin-Dependent, 12 5 Carcinoma, Hepatocellular 5 Carcinoma 5 Neoplasm Metastasis 4 Recurrent Squamous Cell Lung Carcinoma 3 Multiple Myeloma 3 Mouth Neoplasms 3 Mesothelioma 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Follicular 3 Kidney Neoplasms 3 Esophageal Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Renal Cell 3 Uterine Cervical Neoplasms 2 Urothelial Cancer 2

Interventions

tremelimumab 1 durvalumab 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03702179 2024-12-05

IMMUNOPRESERVE

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡